Biochemical reaction products of nitric oxide as quantitative markers of primary pulmonary hypertension

American Journal of Respiratory and Critical Care Medicine

Volumn 158, Issue 3, 1998, Pages 917-923

  Kaneko, F Takao ^a   Arroliga, Alejandro C ^a   Dweik, Raed A ^a   Comhair, Suzy A ^a   Laskowski, Daniel ^a   Oppedisano, Rita ^a   Thomassen, Mary Jane ^a   Erzurum, Serpil C ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; BIOCHEMICAL MARKER; GLUTATHIONE PEROXIDASE; NITRIC OXIDE; OXIDIZING AGENT; SUPEROXIDE DISMUTASE;

ADULT; ARTICLE; BLOOD LEVEL; CHEMICAL REACTION; CLINICAL ARTICLE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; HEART CATHETERIZATION; HUMAN; LUNG ARTERY PRESSURE; PATHOGENESIS; PRIORITY JOURNAL; PULMONARY HYPERTENSION;

EID: 0031783406     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.158.3.9802066     Document Type: Article

References (51)

1. Rubin, L. J. 1997. Primary pulmonary hypertension. N. Engl. J. Med. 336:111-117.
2. D'Alonzo, G. E., R. J. Barst, S. M. Ayres, E. H. Bergofsky, B. H. Brundage, K. M. Detre, A. P. Fishmann, R. M. Goldring, B. M. Groves, J. T. Kernis, P. S. Levy, G. G. Pietra, L. M. Reid, J. T. Reeves, S. Rich, C. E. Vreim, G. W. Williams, and M. Wu. 1991. Survival in patients with primary pulmonary hypertension, results from a national prospective registry. Ann. Intern. Med. 115:343-349.
3. Sandoval, J., O. Bauerle, A. Palomar, A. Gomez, M. L. Martinez-Guerra, M. Beltran, and M. Guerrero. 1994. Survival in primary pulmonary hypertension, validation of a prognostic equation. Circulation 89:1733-1744.
4. Giaid, A., and D. Saleh. 1995. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. 333:214-221.
5. Stamler, J. S., E. Loh, M. A. Roddy, K. E. Currie, and M. A. Creager. 1994. Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. Circulation 89:2035-2040.
6. Cooper, C. J., M. J. Landzberg, T. J. Anderson, F. Charbonneau, M. A. Creager, P. Ganz, and A. P. Selwyn. 1996. Role of nitric oxide in the local regulation of pulmonary vascular resistance in humans. Circulation 93:266-271.
7. Reddy, V. M., J. Wong, J. R. Liddicoat, M. Johengen, R. Chang, and J. R. Fineman. 1996. Altered endothelium-dependent responses in lambs with pulmonary hypertension and increased pulmonary blood flow. Am. J. Physiol. 271:H562-H570.
8. Blitzer, M. L., E. Loh, M. A. Roddy, J. S. Stamler, and M. A. Creager. 1996. Endothelium-derived nitric oxide regulates systemic and pulmonary vascular resistance during acute hypoxia in humans. J. Am. Coll. Cardiol. 28:591-596.
9. Barnes, P. J., and M. G. Belvisi. 1993. Nitric oxide and lung disease. Thorax 48:1034-1043.
10. Gustafsson, L. E., A. M. Leone, M. G. Persson, N. P. Wiklund, and S. Moncada. 1991. Endogenous nitric oxide is present in the exhaled air of rabbits, guinea pigs and humans. Biochem. Biophys. Res. Commun. 181:852-857.
11. Guo, F. H., H. R. De Raeve, T. W. Rice, D. J. Stuehr, F. B. J. M. Thunnissen, and S. C. Erzurum. 1995. Continuous nitric oxide synthesis by inducible nitric oxide synthase in normal human airway epithelium in vivo. Proc. Natl. Acad. Sci. U.S.A. 92:7809-7813.
12. Kobzik, L., D. S. Bredt, C. J. Lowestein, J. Drazen, B. Gaston, D. Sugarbaker, and J. S. Stamler. 1993. Nitric oxide synthase in human and rat lung: immunocytochemical and histochemical localization. Am. J. Respir. Cell Mol. Biol. 9:371-377.
13. Riley, M. S., J. Pórszász, J. Miranda, M. P. K. J. Engelen, B. Brundage, and K. Wasserman. 1997. Exhaled nitric oxide during exercise in primary pulmonary hypertension and pulmonary fibrosis. Chest 111:44-50.
14. Cremona, G., T. Higenbottam, C. Borland, and B. Mist. 1994. Mixed expired nitric oxide in primary pulmonary hypertension in relation to lung diffusion capacity. Q. J. Med. 87:547-551.
15. Xue, C., and R. A. Johns. 1995. Endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. 333: 1642-1644.
16. Xue, C., and R. A. Johns. 1996. Upregulation of nitric oxide synthase correlates temporally with onset of pulmonary vascular remodeling in the hypoxic rat. Hypertension 28:743-753.
17. Pepke-Zaba, J., T. W. Higenbottam, A. T. Dinh-Xuan, D. Stone, and J. Wallwork. 1991. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet 338:1173-1174.
18. The Neonatal Inhaled Nitric Oxide Study Group. 1997. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. N. Engl. J. Med. 336:597-604.
19. Roberts, J. D., J. R. Fineman, F. C. Morin, III, P. W. Shaul, S. Rimar, M. D. Schreiber, R. A. Polin, M. S. Zwass, M. M. Zayek, I. Gross, M. A. Heymann, and W. M. Zapol. 1997. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. N. Engl. J. Med. 336: 605-610.
20. Tuder, R. M., B. Groves, D. B. Badesch, and N. F. Voelkel. 1994. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am. J. Pathol. 144: 275-285.
21. Humbert, M., G. Monti, F. Brenot, O. Sitbon, A. Portier, L. Grangeot-Keros, P. Duroux, P. Galanaud, G. Simonneau, and D. Emilie. 1995. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am. J. Respir. Crit. Care Med. 151:1628-1631.
22. Mark, E. J., E. D. Patalas, H. T. Chang, R. J. Evans, and S. Kessler. 1997. Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine. N. Engl. J. Med. 337:602-606.
23. Wink, D. A., I. Hanbauer, M. B. Grisham, F. Laval, R. W. Nims, J. Laval, J. Cook, P. Pacelli, J. Liebmann, M. Krishna, P. C. Ford, and J. B. Mitchell. 1996. Chemical biology of nitric oxide: regulation and protective and toxic mechanisms. Curr. Top. Cell Regul. 34:159-187.
24. Gaston, B., J. M. Drazen, J. Loscalzo, and J. S. Stamler. 1994. The biology of nitrogen oxides in the airways. Am. J. Respir. Crit. Care Med. 149:538-551.
25. Xia, Y., and J. L. Zweier. 1997. Superoxide and peroxynitrite generation from inducible nitric oxide synthase in macrophages. Proc. Natl. Acad. Sci. U.S.A. 94:6954-6958.
26. Stamler, J. S. 1996. A radical vascular connection. Nature 380:108-111.
27. Stuart, R., D. R. Dantzker, S. M. Ayres, E. H. Bergofsky, B. H. Brundage, K. M. Detre, A. P. Fishman, R. M. Goldring, B. M. Groves, S. K. Koerner, P. C. Levy, L. M. Reid, C. E. Vreim, and G. W. Williams. 1987. Primary pulmonary hypertension: a national prospective study. Ann. Intern. Med. 107:216-223.
28. Dweik, R. A., D. Laskowski, H. M. Abu-Soud, F. T. Kaneko, R. Hutte, D. J. Stuehr, and S. C. Erzurum. 1998. Nitric oxide synthesis in the lung: regulation by oxygen through a kinetic mechanism. J. Clin. Invest. 101:660-666.
29. Guo, F., K. Uetani, S. J. Haque, B. R. G. Williams, R. A. Dweik, F. B. J. M. Thunnissen, W. Calhoun, and S. C. Erzurum. 1997. Interferon-γ and interleukin-4 stimulate prolonged expression of inducible nitric oxide synthase in human airway epithelium through synthesis of soluble mediators. J. Clin. Invest. 100:829-838.
30. 2. J. Appl. Physiol. 75:1256-1262.
31. De Raeve, H. R., F. B. J. M. Thunnissen, F. T. Kaneko, F. H. Guo, M. Lewis, M. S. Kavuru, M. Secic, M. J. Thomassen, and S. C. Erzurum. 1997. Decreased Cu,Zn-SOD activity in asthmatic airway epithelium: correction by inhaled corticosteroid in vivo. Am. J. Physiol. (Lung Cell Mol. Physiol.) 272:L148-L154.
32. Adams, J. D., B. H. Lauterburg, and J. R. Mitchell. 1984. Plasma glutathione and glutathione disulfide in the rat: regulation and response to oxidative stress. J. Pharmacol. Exp. Ther. 227:749-754.
33. Chung, S., and H. Fung. 1990. Identification of the subcellular site for nitroglycerin metabolism to nitric oxide in bovine coronary smooth muscle cells. J. Pharmacol. Exp. Ther. 253:614-619.
34. Perry, J. H. 1950. Chemical engineer's handbook, 3rd ed. McGraw-Hill Publishers, New York. 675.
35. Palmer, R. M. J., A. G. Ferrige, and S. Moncada. 1987. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327:524-526.
36. Ignarro, L. J., G. M. Buga, K. S. Wood, R. E. Byrns, and G. Chaudhuri. 1987. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc. Natl. Acad. Sci. U.S.A. 84: 9265-9269.
37. Stuehr, D. J., and O. W. Griffith. 1992. Mammalian nitric oxide synthases. Adv. Enzymol. Relat. Areas Mol. Biol. 65:287-346.
38. 2 and endothelium-dependent cerebral arteriolar dilation: implications for the identity of endothelium-derived relaxing factor generated by acetylcholine. Hypertension 16:162-169.
39. Zemin, X., C. Tong, H. L. Pan, S. E. Cerda, and J. C. Eisenach. 1997. Intravenous morphine increases release of nitric oxide from spinal cord by an α-adrenergic and cholinergic mechanism. J. Neurophysiol. 78: 2072-2078.
40. Magazine, H. I., Y. Liu, T. V. Bilfinger, G. L. Fricchione, and G. B. Stefano. 1996. Morphine induced conformational changes in human monocytes, granulocytes, and endothelial cells and in invertebrate immunocytes and microglia are mediated by nitric oxide. J. Immunol. 156:4845-4850.
41. Liao, J. K., J. L. Zulueta, F. S. Yu, H. B. Peng, C. G. Cote, and P. M. Hassoun. 1995. Regulation of bovine endothelial constitutive nitric oxide synthase by oxygen. J. Clin. Invest. 96:2661-2666.
42. Melillo, G., T. Musso, A. Sica, L. S. Taylor, G. W. Cox, and L. Varesio. 1995. A hypoxia responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter. J. Exp. Med. 182:1683-1693.
43. Morris, P. E., and G. R. Bernard. 1994. Significance of glutathione in lung disease and implications for therapy. Am. J. Med. Sci. 307:119-127.
44. Cantin, A. M., and R. Begin. 1991. Glutathione and inflammatory disorders of the lung. Lung 169:123-138.
45. Cantin, A. M., S. L. North, R. C. Hubbard, and R. G. Crystal. 1987. Normal alveolar epithelial lining fluid contains high levels of glutathione. J. Appl. Physiol. 63:152-157.
46. Smith, L. J., M. Houston, and J. Anderson. 1993. Increased levels of glutathione in bronchoalveolar lavage fluid from patients with asthma. Am. Rev. Respir. Dis. 147:1461-1464.
47. Botney, M. D., L. Bahadori, and L. I. Gold. 1994. Vascular remodeling in primary pulmonary hypertension. Potential role for transforming growth factor-β. Am. J. Pathol. 144:286-295.
48. Bahadori, L., J. Milder, L. Gold, and M. Botney. 1995. Active macrophage-associated TGF-β co-localizes with type I procollagen gene expression in atherosclerotic human pulmonary arteries. Am. J. Pathol. 146:1140-1149.
49. Giaid, A., M. Yanagisawa, D. Langleben, R. P. Michel, R. Levy, H. Shennib, S. Kimura, T. Masaki, W. P. Duguid, and D. J. Stewart. 1993. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. 328:1732-1739.
50. Stewart, D. J., R. D. Levy, P. Cernacek, and D. Langleben. 1991. Increase plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann. Intern. Med. 114:464-469.
51. Abenhaim, L., Y. Monde, F. Brenot, S. Rich, J. Benichou, X. Kurz, T. Higenbottam, C. Oakley, E. Wouters, M. Aubier, G. Simonneau, and B. Begaud. 1996. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N. Engl. J. Med. 335:609-616.